| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1060028013512474 |
| P698 | PubMed publication ID | 24259653 |
| P2093 | author name string | Eun Kyoung Chung | |
| Michael B Kays | |||
| S Christian Cheatham | |||
| Megan R Fleming | |||
| Joetta M Juenke | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007) | Q28270131 | ||
| Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010 | Q29614504 | ||
| Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients | Q33553063 | ||
| Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults | Q34510697 | ||
| Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections | Q35759054 | ||
| National, regional, and global trends in adult overweight and obesity prevalences | Q36526941 | ||
| Case-control study of drug monitoring of β-lactams in obese critically ill patients | Q36558332 | ||
| Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists | Q36582692 | ||
| Antimicrobial dosing considerations in obese adult patients | Q36892796 | ||
| Implications of obesity for drug therapy: limitations and challenges | Q37883897 | ||
| Dosing of antibiotics in obesity | Q38049974 | ||
| Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia | Q40519156 | ||
| Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients | Q42254710 | ||
| Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients | Q42656891 | ||
| Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States | Q43077283 | ||
| Adjustment of dosing of antimicrobial agents for bodyweight in adults. | Q43532401 | ||
| Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients | Q43890466 | ||
| Continuous infusion versus intermittent administration of meropenem in critically ill patients | Q44483233 | ||
| Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. | Q45954223 | ||
| Estimation of creatinine clearance in morbidly obese patients | Q46082183 | ||
| Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents | Q46106142 | ||
| Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis | Q46472365 | ||
| Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study | Q46672001 | ||
| Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. | Q54446298 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| meropenem | Q421670 | ||
| pharmacodynamics | Q725307 | ||
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 178-186 | |
| P577 | publication date | 2013-11-14 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. | |
| P478 | volume | 48 |
| Q38751264 | Carbapenem susceptibility breakpoints, clinical implications with the moving target. |
| Q40067964 | Comprehensive Guidance for Antibiotic Dosing in Obese Adults |
| Q30362353 | Dosing of antibacterial agents in obese adults: does one size fit all? |
| Q38583848 | Interaction of obesity and infections |
| Q41349399 | Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial in |
| Q39484436 | Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients |
| Q37538609 | Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery |
| Q36076101 | Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery |
| Q36438971 | Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. |
| Q59263334 | Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age |
| Q40752468 | Therapeutic management of peritonitis: a comprehensive guide for intensivists |
| Q40172540 | What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? |
Search more.